## For Research Use Only

## Recombinant Human Endoglin/CD105 protein (His Tag)



Catalog Number: Eg0587

**Basic Information** 

Species: Human

Purity: >90 %, SDS-PAGE

Tag: His Tag

**Technical Specifications** 

Purity: >90 %, SDS-PAGE

**Endotoxin Level:** 

<0.1 EU/ µ g protein, LAL method

HEK293-derived Human Endoglin protein Glu26-Gly586 (Accession# P17813-1) with a His tag at the C-terminus.

GeneID:

2022

Accession: P17813-1

**Predicted Molecular Mass:** 61.5 kDa

**SDS-PAGE:** 

65-85 kDa, reducing (R) conditions

Lyophilized from 0.22  $\,\mu$  m filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.

**Biological Activity** 

Not tested

Storage and Shipping

It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

- Until expiry date, -20°C to -80°C as lyophilized proteins.
- 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.

The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Reconstitution

Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.

Background

Endoglin (ENG, CD105) is a homodimeric cell membrane glycoprotein of 180 kDa, composed of disulphide-Entoglin (EDA), CDID3) is a find infind miler celt interibrate glycoprotein of 180 kJ, Composed of insulprince-linked subunits of 90-95 kDa. Endoglin is a proliferation-associated and hypoxia-inducible protein mainly expressed on vascular endothelial cells. It acts as an accessory receptor for transforming growth factor beta (TFG-β) and is involved in vascular development and remodelling. The important role of Endoglin in angiogenesis and in tumor progression makes it an ideal target for antiangiogenic therapy and a good marker for tumor prognosis. The extracellular domain of membrane-bound Endoglin can be proteolytically cleaved, releasing a soluble form of Endoglin (sCD105). Increased levels of SCD105 are linked to the pathogenesis of severe vascular disease, and also correlate with poor prognosis in patients suffering from various types of cancer.

References

- Cheifetz S et al. (1992) Journal of Biological Chemistry. 267(27): 19027-19030.
  Fonsatti E. et al. (2003) Oncogene. 22(42): 6557-6563.
  Nassiri F. et al. (2011) Anticancer research. 31(6): 2283-2290.
  Duff S E et al. (2003) The FASEB Journal. 17(9): 984-992.

- 5. Pappa C A. et al. (2013) Hematological oncology.31(4): 201-205.

**Synonyms** 

CD105, END, Endoglin, ENG, HHT1

## **Selected Validation Data**



Purity of Recombinant Human Endoglin was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.